Forte Biosciences Inc (FBRX) Stock Price, Quote & News

Company Profile

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Industry: Biotechnology

Sector: Healthcare

Phone: 310 618 6994

Website: www.fortebiorx.com

Address:

3060 Pegasus Park Drive, Building 6, Dallas, United States

Mrstock2255 Nov. 13 at 10:25 PM

$FBRX $FCFS $FCX $FDIG $FDS

0 · Reply

deedeethegenius Nov. 13 at 6:33 PM

1. $KURA (Nov 30) - Best risk/reward for conservative biotech investors 2. $COGT (Dec) - Already validated with +135% move; multiple shots on goal 3. $FBRX (Q4) - Strongest unusual options signal (1,663% spike

0 · Reply

Investmann Oct. 14 at 7:34 PM

$FBRX country club is talking about

0 · Reply

porky1963 Oct. 11 at 8:00 PM

$FBRX well lets try and predict the next few weeks,will biotech come out on top.i think so.maybe a roller coaster for crypto.

0 · Reply

Doozio Oct. 11 at 6:26 PM

$XBI don’t $FOLD unless yo gotta $AXSM body! If so? $FBRX about it . 🐒🍌🧠⏰♾️

0 · Reply

Doozio Oct. 11 at 3:32 PM

Gotta be on $DRUG zzzzzz to still be bullish. As long as no faatch 💣 lands. $FBRX etaboutit. 🐒🍌🧠⏰♾️

0 · Reply

Doozio Oct. 11 at 12:13 AM

Chop chop huckleberries. $FBRX etaboutit! 🐒🍌🧠⏰♾️

0 · Reply

Investmann Oct. 3 at 8:08 PM

$FBRX next stop 20$

0 · Reply

Investmann Sep. 30 at 2:55 PM

$FBRX big whales in.

0 · Reply

AngieRodriguez645 Sep. 21 at 1:01 PM

$FBRX Biotech with novel approach. Pre-revenue volatility. Chart shows high risk/reward. Avoid.

0 · Reply

Forte Biosciences, Inc. to Present at Upcoming Healthcare Conferences

Oct 3, 2025, 4:01 PM EDT - 5 weeks ago

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

Sep 15, 2025, 9:00 AM EDT - 2 months ago

Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium

Aug 14, 2025, 4:01 PM EDT - 3 months ago

Forte Biosciences, Inc. Announces Results and Provides Update

Jun 25, 2025, 12:28 AM EDT - 5 months ago

Forte Biosciences Announces Pricing of $75 Million Public Offering

Jun 24, 2025, 4:01 PM EDT - 5 months ago

Forte Biosciences Announces Proposed Public Offering

Jun 23, 2025, 7:18 AM EDT - 5 months ago

Forte Biosciences Announces Positive Data in FB102 Celiac Disease Phase 1B Study

Mar 31, 2025, 9:00 AM EDT - 8 months ago

Forte Biosciences, Inc. Announces Results and Provides Clinical Update

Feb 3, 2025, 9:00 AM EST - 10 months ago

Forte Biosciences, Inc. to Present at Upcoming Investor Meetings

Nov 25, 2024, 9:00 AM EST - 1 year ago

Forte Biosciences to Host R&D Day December 3, 2024

Nov 20, 2024, 9:00 AM EST - 1 year ago

Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune Indications

Nov 14, 2024, 4:01 PM EST - 1 year ago

Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business Update

Aug 14, 2024, 4:01 PM EDT - 1 year ago

Forte Biosciences, Inc. Announces Second Quarter 2024 Results and Provides Business Update

May 13, 2024, 4:05 PM EDT - 1 year ago

Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update

Mar 18, 2024, 4:05 PM EDT - 1 year ago

Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update

Dec 1, 2023, 4:01 PM EST - 2 years ago

Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules

Nov 13, 2023, 4:01 PM EST - 2 years ago

Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update

Sep 14, 2023, 10:50 AM EDT - 2 years ago

ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company's Upcoming Annual Meeting

Sep 6, 2023, 3:15 PM EDT - 2 years ago

Concerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company's Boardroom

Aug 25, 2023, 8:00 AM EDT - 2 years ago

Concerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to Stockholders

Aug 14, 2023, 4:01 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business Update

Aug 1, 2023, 4:01 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102

May 15, 2023, 4:01 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business Update

Mar 31, 2023, 4:05 PM EDT - 2 years ago

Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update

Jan 12, 2023, 4:05 PM EST - 3 years ago

Mr. David Gryska Appointed to Forte Biosciences Board of Directors

Nov 14, 2022, 4:01 PM EST - 3 years ago

Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors

Nov 14, 2022, 4:01 PM EST - 3 years ago

Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update

Aug 17, 2022, 8:00 AM EDT - 3 years ago

Camac Partners Condemns Forte Biosciences' Seemingly Defensive and Unjustifiable Capital Raise

Aug 15, 2022, 4:05 PM EDT - 3 years ago

Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update

Jun 7, 2022, 9:00 AM EDT - 3 years ago

Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President

May 16, 2022, 9:00 AM EDT - 3 years ago

Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update

Sep 6, 2021, 12:42 PM EDT - 4 years ago

INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm

Sep 3, 2021, 2:31 PM EDT - 4 years ago

Why Forte Biosciences Stock Is Down Over 80% Today

Sep 3, 2021, 12:19 PM EDT - 4 years ago

A small biotech firm just plummeted 82% after abandoning a drug candidate due to failed phase 2 trial

Sep 3, 2021, 7:21 AM EDT - 4 years ago

Forte Biosciences stock plunges more than 80% after 'disappointing' trial results of atopic dermatitis treatment

Sep 2, 2021, 5:47 PM EDT - 4 years ago

Forte Biosciences Just Plummeted 80%: Here's Why

Sep 2, 2021, 4:05 PM EDT - 4 years ago

Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance

Aug 16, 2021, 4:05 PM EDT - 4 years ago

Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7

May 11, 2021, 7:24 AM EDT - 4 years ago

Forte Biosciences, Inc. (FBRX) CEO Paul Wagner on Q1 2021 Results - Earnings Call Transcript

May 10, 2021, 4:05 PM EDT - 4 years ago

Forte Biosciences, Inc. Announces First Quarter 2021 Results and Provides a General Business Update

May 3, 2021, 4:30 PM EDT - 4 years ago

Forte Biosciences, Inc. to Announce First Quarter 2021 Results and Provide a General Business Update

Apr 9, 2021, 6:07 AM EDT - 5 years ago

Forte Biosciences: Microbiome Therapeutics For Skin Disease

Apr 8, 2021, 6:59 PM EDT - 5 years ago

Forte Biosciences: FB-401 Could Become The First Line Topical Therapy In Atopic Dermatitis Market

Mar 29, 2021, 12:10 PM EDT - 5 years ago

Week 13 MDA Breakout Stocks - April 2021: Short-Term Picks To Give You An Edge

AMGN AXP CAT IMOM JPM UNH VRA

Mar 24, 2021, 8:00 AM EDT - 5 years ago

Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update

Mar 17, 2021, 4:05 PM EDT - 5 years ago

Forte Biosciences, Inc. to Announce 4Q and Full Year 2020 Results and Provide a General Business Update

Feb 23, 2021, 4:01 PM EST - 5 years ago

Forte Biosciences, Inc. to Present at the Chardan Annual Microbiome Medicines Summit on March 8th

Feb 18, 2021, 4:01 PM EST - 5 years ago

Forte Biosciences, Inc. to Present at the Cowen Annual Health Care Conference on March 1st

Mrstock2255 Nov. 13 at 10:25 PM

$FBRX $FCFS $FCX $FDIG $FDS

0 · Reply

deedeethegenius Nov. 13 at 6:33 PM

0 · Reply

Investmann Oct. 14 at 7:34 PM

$FBRX country club is talking about

0 · Reply

porky1963 Oct. 11 at 8:00 PM

$FBRX well lets try and predict the next few weeks,will biotech come out on top.i think so.maybe a roller coaster for crypto.

0 · Reply

Doozio Oct. 11 at 6:26 PM

$XBI don’t $FOLD unless yo gotta $AXSM body! If so? $FBRX about it . 🐒🍌🧠⏰♾️

0 · Reply

Doozio Oct. 11 at 3:32 PM

Gotta be on $DRUG zzzzzz to still be bullish. As long as no faatch 💣 lands. $FBRX etaboutit. 🐒🍌🧠⏰♾️

0 · Reply

Doozio Oct. 11 at 12:13 AM

Chop chop huckleberries. $FBRX etaboutit! 🐒🍌🧠⏰♾️

0 · Reply

Investmann Oct. 3 at 8:08 PM

$FBRX next stop 20$

0 · Reply

Investmann Sep. 30 at 2:55 PM

$FBRX big whales in.

0 · Reply

AngieRodriguez645 Sep. 21 at 1:01 PM

$FBRX Biotech with novel approach. Pre-revenue volatility. Chart shows high risk/reward. Avoid.

0 · Reply

porky1963 Sep. 19 at 7:45 AM

$FBRX run away tray comeing.

0 · Reply

Doozio Sep. 19 at 5:03 AM

$FBRX

1 · Reply

dongslayer Sep. 15 at 4:06 PM

$FBRX anybody here?

1 · Reply

Alpha_Instict09 Sep. 6 at 12:50 PM

$FBRX I remember watching this one dew years ago and I almost bought...luckily I didn't

0 · Reply

porky1963 Aug. 30 at 9:54 AM

@JarvisFlow $FBRX stabale at $11.00 with quite a high volume looking good next few weeks.

0 · Reply

StressTestIQ Aug. 27 at 4:50 AM

$FBRX price stabilizing, could attract dip buyers.

0 · Reply

porky1963 Aug. 25 at 2:08 PM

$FBRX feels like that i am the only one here.

0 · Reply

porky1963 Aug. 20 at 7:55 AM

$FBRX strange moves again and insiders seem to hold a good chunk and keep adding like me.$CRE

0 · Reply

d_risk Aug. 17 at 4:36 PM

$FBRX - Forte Biosciences, Inc. - 10Q - Updated Risk Factors FBRX flags heightened risks from clinical trial setbacks, heavy cash burn, sole reliance on FB102, expanded regulatory and compliance exposures, IP and third-party dependencies, market volatility, and new legal, fraud, and misconduct concerns—plus potential dilution and stock price pressure from future financings and insider sales. #Biotechnology #MarketVolatility #IntellectualProperty #RegulatoryCompliance #ClinicalTrialRisks 🟢 Added 🟠 Removed https://d-risk.ai/FBRX/10-Q/2025-08-14

0 · Reply

JarvisFlow Aug. 15 at 12:30 PM

Chardan Capital has updated their rating for Forte Biosciences ( $FBRX ) to Buy with a price target of 61.

0 · Reply

porky1963 Aug. 15 at 10:30 AM

$FBRX not all bad news then,seems to be looking up in 2026,will add a few premarket.will it make a splash today.

0 · Reply

porky1963 Aug. 12 at 8:59 AM

$CRE $FBRX believe there is a meeting this week and we will get to know more .

0 · Reply

Market Cap	179.78M
Revenue (ttm)	0.00
Net Income (ttm)	-35.48M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	44,400
Avg Vol	93,032
Day's Range	N/A - N/A
Shares Out	12.43M
Stochastic %K	77%
Beta	2.98
Analysts	Strong Sell
Price Target	$63.33